Dosage and administration
For oral administration only.

1. For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections in dogs and cats, administer either:
•5.5 mg/kg of bodyweight every 12 hours for 7 to 10 days, or
•11 mg/kg of bodyweight every 24 hours for 7 to 10 days
If no clinical response is seen within 4 days, redetermine the diagnosis. To help provide anti-microbial cover during dental procedures, a 10 day course is recommended. This should be initiated five days before dental therapy and continued for five days thereafter. In dogs, treatment may be extended to a maximum of 28 days based on clinical judgement.

2. For the treatment of superficial pyoderma in dogs, administer either:
•5.5 mg/kg of bodyweight every 12 hours
•11 mg/kg of bodyweight every 24 hours
Therapy of canine superficial pyoderma is usually recommended for 21 days, with extension of therapy based on clinical judgement.

3. For the treatment of osteomyelitis in dogs, administer:
•11 mg/kg of bodyweight every 12 hours for a minimum of 28 days
If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.

Contra-indications, warnings, etc
The use of Antirobe Capsules is contra-indicated in animals which are hypersensitive to preparations containing clindamycin or lincomycin.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin by these species may result in severe gastro-intestinal disturbance.
Clindamycin and erythromycin show parallel resistance. Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolide antibiotics.
Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Antirobe Capsules should be used with caution in animals receiving such agents.
Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they antagonise each other at their site of action at the 50S ribosomal sub-unit.
Vomiting and diarrhoea have occasionally been observed.
Antirobe sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.
While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches/queens or breeding male dogs/cats has not been established.
Wash hands after handling the capsules.